Thomas Dobyns, MD
Family Medicine · Madison Heights, VANPI 1336127323
Payments from drug & device makers
Across 297 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$958
- AbbVie$741
- Lilly USA, LLC$353
- Johnson & Johnson$348
- Novo Nordisk$325
- GSK$268
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,39598%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $958 |
| AbbVie(2 entities) | 80 | $741 |
| Lilly USA, LLC | 20 | $353 |
| Johnson & Johnson | 25 | $348 |
| Novo Nordisk | 17 | $325 |
| GSK | 18 | $268 |
| Boehringer Ingelheim | 10 | $168 |
| Amgen | 10 | $164 |
| Pfizer | 7 | $116 |
| Astellas Pharma US Inc | 3 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $96 |
| Idorsia Pharmaceuticals US Inc | 2 | $93 |
| Exact Sciences | 4 | $93 |
| Sanofi-aventis U.S. LLC | 6 | $91 |
| Amarin Pharma, Inc. | 4 | $69 |
| Corium, LLC | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Merck | 3 | $46 |
| Dexcom, Inc. | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Abbott | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Novartis | 2 | $31 |
| Lundbeck LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
How this compares
$4,475 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 106 | $86,411 |
| EliquisApixaban | 87 | $81,488 |
| FarxigaDapagliflozin Propanediol | 71 | $67,273 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $66,904 |
| OzempicSemaglutide | 56 | $53,866 |
| MounjaroTirzepatide | 34 | $50,676 |
| TrulicityDulaglutide | 36 | $44,545 |
| XareltoRivaroxaban | 46 | $38,857 |
| JardianceEmpagliflozin | 34 | $38,665 |
| LinzessLinaclotide | 35 | $35,924 |
| TradjentaLinagliptin | 22 | $20,987 |
| MyrbetriqMirabegron | 30 | $17,124 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $15,238 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $14,997 |
| VascepaIcosapent Ethyl | 18 | $6,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $353 | $95,22170 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $268 | $87,274107 claims |
| MerckJanuvia | $46 | $86,411106 claims |
| PfizerEliquis | $116 | $81,48887 claims |
| AstraZenecaFarxiga, Symbicort | $958 | $69,90482 claims |
| Boehringer IngelheimJardiance, Tradjenta | $168 | $59,65256 claims |
| Novo NordiskOzempic | $325 | $53,86656 claims |
| Johnson & JohnsonXarelto | $348 | $38,85746 claims |
| AbbVieLinzess | $741 | $35,92435 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $91 | $19,24453 claims |
| Astellas Pharma US IncMyrbetriq | $112 | $17,12430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Madison Heights
- Verna GuanzonMadison Heights$27K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.